This study tests a personalized DNA vaccine (GNOS-PV02) combined with an immune booster and the immunotherapy drug pembrolizumab in 36 adults with advanced hepatocellular carcinoma (HCC). The vaccine is custom-made for each patient based on their tumor's unique genetic markers. T…
Phase: PHASE1, PHASE2 • Sponsor: Geneos Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC